Boehringer Ingelheim will make a significant investment in biopharmaceutical production at its Vienna (Austria) site. There the research-driven pharmaceutical company will establish a new large-scale biopharmaceutical production facility for active ingredients manufactured using cell cultures. With the roughly half billion euro investment Boehringer Ingelheim will also create more than 400 new jobs in the Austrian capital. The exact investment and job numbers will be established as details are ironed out.
“This is a decision for Europe as a pharma location,” said Professor Dr Andreas Barner, Chairman of the Board of Managing Directors at Boehringer Ingelheim. “We took a close look at various international options as part of the investment decision, also considering the research environment at potential sites. The clincher for Vienna was ultimately the company’s desire to additionally secure the market supply of biopharmaceutical products and to balance the risk by establishing a further independent facility.”
In Vienna, Boehringer Ingelheim has up to now produced pharmaceutical active ingredients using microorganisms; over the next few years, cell culture technology will also be transferred there. At the Biberach site, two large-scale facilities for the market launch and cell culture based manufacture of biopharmaceuticals have already been operating successfully for many years. Biberach will remain Boehringer Ingelheim’s largest European cell culture and global launch site for biopharmaceutical products.
“Our own promising biopharmaceutical development projects and the heavy market demand for contract manufacturing were the basis for our decision to invest long-term in our biopharmaceuticals activities to this extent,” explained Dr Wolfgang Baiker, member of the Board of Managing Directors responsible for biopharmaceuticals and operations. The investment will strengthen Boehringer Ingelheim’s international biopharmaceutical network and enhance its leading position in the market. The new production plant will go into operation by 2021.
Boehringer Ingelheim is one of the world’s largest manufacturers of biopharmaceutical medicines. With over 35 years of experience, the company is an industry pioneer and has manufactured more than 25 biopharmaceutical products for patients worldwide.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.
For more information please visit www.boehringer-ingelheim.com